Showing results (171-180 of 192) with videos related to
Sort By:
Pageof 20
NPJ Genomic Medicine|January 14, 2022
Evidence that the Ser192Tyr/Arg402Gln in cis Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B)Siying Lin, Aida Sanchez-Bretaño, Joseph S Leslie, et al.Nature Medicine|November 11, 2024
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trialKate Cwynarski, Gloria Iacoboni, Eleni Tholouli, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2026
Antibody Format Matters: A Comparative Analysis of VHH and scFv Domains Reveals Superior In Vivo CAR T Cell Function with VHH DomainsAlexander Kinna, Preeta Datta, Reyisa Bughda, et al.Journal for Immunotherapy of Cancer|July 3, 2023
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapyLydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, et al.ERJ Open Research|April 20, 2023
The Palestinian primary ciliary dyskinesia population: first results of the diagnostic and genetic spectrumNisreen Rumman, Mahmoud R Fassad, Corine Driessens, et al.NIHR Open Research|August 15, 2024
A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocolLaurna Bullock, Elaine Nicholls, Andrea Cherrington, et al.Thorax|September 1, 2018
Risk factors for situs defects and congenital heart disease in primary ciliary dyskinesiaSunayna Best, Amelia Shoemark, Bruna Rubbo, et al.Elife|January 17, 2023
Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disordersLydie Burglen, Evelien Van Hoeymissen, Leila Qebibo, et al.The European Respiratory Journal|January 22, 2021
Topological data analysis reveals genotype-phenotype relationships in primary ciliary dyskinesiaAmelia Shoemark, Bruna Rubbo, Marie Legendre, et al.Nature Communications|February 21, 2024
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignanciesMathieu Ferrari, Matteo Righi, Vania Baldan, et al.Pageof 20